Toll-Like Receptor Expression in the Blood and Brain of Patients and a Mouse Model of Parkinson's Disease
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Accumulating evidence supports a role for the immune system in the pathogenesis of Parkinson's disease. Importantly, recent preclinical studies are now suggesting a specific contribution of inflammation to the α-synuclein-induced pathology seen in this condition. METHODS: We used flow cytometry and western blots to detect toll-like receptor 2 and 4 expression in blood and brain samples of Parkinson's disease patients and mice overexpressing human α-synuclein. To further assess the effects of α-synuclein overexpression on the innate immune system, we performed a longitudinal study using Thy1.2-α-synuclein mice that expressed a bicistronic DNA construct (reporter genes luciferase and green fluorescent protein) under the transcriptional control of the murine toll-like receptor 2 promoter. RESULTS: Here, we report increases in toll-like receptors 2 and 4 expression in circulating monocytes and of toll-like receptor 4 in B cells and in the caudate/putamen of Parkinson's disease patients. Monthly bioluminescence imaging of Thy1.2-α-synuclein mice showed increasing toll-like receptor 2 expression from 10 months of age, although no change in toll-like receptor 2 and 4 expression was observed in the blood and brain of these mice at 12 months of age. Dexamethasone treatment starting at 5 months of age for 1 month significantly decreased the microglial response in the brain of these mice and promoted functional recovery as observed using a wheel-running activity test. CONCLUSION: Our results show that toll-like receptors 2 and 4 are modulated in the blood and brain of Parkinson's disease patients and that overexpression of α-synuclein leads to a progressive microglial response, the inhibition of which has a beneficial impact on some motor phenotypes of an animal model of α-synucleinopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Toll-like receptor (TLR)2 and TLR4 expression in the brain of Parkinson’s disease (PD) patients. (A-B) Western blot quantification of TLR2, TLR4, and molecules involved in their downstream pathways (myeloid differentiation primary response gene (88) [MyD88], TIR-less splice variant of TIR-domain-containing adapter-inducing interferon-β [TRIS], nuclear factor κB [NF-κB]in the striatum of PD patients (n=7) compared to age- and gender-matched controls (CTL or C) (n=6). Data are expressed as a ratio over β-actin. All data are expressed as group means±SEM. Statistical analyses were performed using an unpaired Student’s t test with a Welch correction in case of unequal variance. *P<.05; **P<.01.](https://figures.cochat.ai/paper-figures/4699b87a783b4139b5544152384eeb27/toll-like-receptor-expression-in-the-blood-and-brain-of-patients-and-a-mouse-figure-2.jpg)
![Figure 3. Toll-like receptor (TLR)2 and TLR4 expression in the brain of Thy1.2-α-synuclein (αSyn)× TLR2-GFP-fluc mice. Schematic diagram of the Thy1.2-αSyn (Rockenstein et al., 2002) and TLR2-GFP-fluc (Lalancette-Hebert et al., 2009) constructs that were used to generate the Thy1.2-αSyn×TLR2-GFP-fluc mice. (B) Immunofluorescent staining of human αSyn (hαSyn) showing none in a littermate nontransgenic for the hαSyn gene and strong expression in the transgenic mouse. Treatment with Proteinase K confirms the presence of αSyn in the substantia nigra of Thy1.2-αSyn×TLR2-GFP-fluc mice. (C) Western blot quantification of TLR2, TLR4, and molecules involved in their pathways (myeloid differentiation primary response gene (88) [MyD88], TIR-less splice variant of TIR-domain-containing adapter-inducing interferon-β [TRIS], Nuclear factor κB [NF-κB]-p65), as well as hαSyn and total αSyn, in the striatum of Thy1.2-αSyn×TLR2-GFP-fluc mice (n=9) compared to wild type×TLR2-GFP-fluc littermates (n=9) at 12 months of age. Western blot data are expressed as a ratio over β-actin. All data are expressed as group means±SEM. Statistical analyses were performed using an unpaired Student’s t test with a Welch correction in case of unequal variance. hαSyn-/-, TLR2-GFP-fluc mice; hαSyn-/-, Thy1.2-αSyn×TLR2-GFP-fluc mice; SNCA, synuclein, Alpha (Non A4 Component Of Amyloid Precursor); TRIS, TIR-less splice variant of TIR-domain-containing adapter-inducing interferon-β (TRIF). Scale bar=100 µm, inset=25 µm, lower row=50 µm.](https://figures.cochat.ai/paper-figures/ab7ba182cb3d400492a3d1aa5bb1d6ba/toll-like-receptor-expression-in-the-blood-and-brain-of-patients-and-a-mouse-figure-3.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased gut permeability with intestine α-synuclein accumulation, elevated blood and brain levels of TLR2 and TLR4, and reduced blood levels of the LPS-binding protein have been detected in subjects with”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [412]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It has been suggested that TLR2 expression is upregulated in PD postmortem human brains.291,292”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [291]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378 · cited 1×
“All patients had been diagnosed according to the diagnostic criteria of the UK PD Society Brain Bank (Hughes et al., 1992).”
MethodSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383 · cited 1×
“The involvement of αSyn to PD pathogenesis is further supported by the fact that overexpression of this protein, as a consequence of either a duplication or triplication of the gene, leads to early-onset PD (Singleton et al., 2003; Chartier-Harlin et al., 2004).”
BackgroundMcGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990 · cited 1×
“It has in fact long been recognized that PD brains are characterized by the presence of a microglial reaction (McGeer et al., 1988; McGeer and McGeer, 2004), which increases with disease duration (Croisier et al.”
BackgroundWiklund, R. A., & Rosenbaum, S. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371606 · Cited by 2,149
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029 · cited 1×
“The involvement of αSyn to PD pathogenesis is further supported by the fact that overexpression of this protein, as a consequence of either a duplication or triplication of the gene, leads to early-onset PD (Singleton et al., 2003; Chartier-Harlin et al., 2004).”
BackgroundLang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994 · cited 2×
“In PD, there is a degeneration of the nigrostriatal dopaminergic pathway with formation of Lewy bodies, which together form the pathological hallmarks of the disease (Lang and Lozano, 1998).”
BackgroundMethodZhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265 · cited 1×
“In particular, aggregated forms of this protein secreted by neurons of the substantia nigra (SN) could do this, leading to the production of pro-inflammatory mediators and thereby exacerbating neuronal death (Zhang et al., 2005; Su et al., 2008; Theodore et al., 2008; Lee et al., 2010).”
BackgroundKim, C., Ho, D.-H., Suk, J.-E., You, S., Michael, S., Kang, J., Joong Lee, S., Masliah, E., Hwang, D., Lee, H.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms2534 · Cited by 856 · cited 3×
“It has recently been reported that oligomers of Syn, but not aggregates, can act as TLR2 ligands (Kim et al., 2013).”
BackgroundInfluentialMicroglial activation and dopamine terminal loss in early Parkinson's disease
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005) · Annals of Neurology · doi:10.1002/ana.20338 · Cited by 843 · cited 1×
“For commercial re-use, please contact journals.permissions@oup.com Background: Accumulating evidence supports a role for the immune system in the pathogenesis of Parkinson’s disease.”
Background
Research works printed but not linked: 6
- 2013, Neurochemical research, 38, 1252, 10.1007/s11064-013-1020-5 · DOI · Paper page
- 2013, Movement disorders : official journal of the Movement Disorder Society, 28, 392, 10.1002/mds.25300 · DOI · Paper page
- 2010, Journal of Biological Chemistry, 285, 12543, 10.1074/jbc.m109.072231 · DOI
- 2009, The Journal of Immunology, 183, 7461, 10.4049/jimmunol.0901517 · DOI · Paper page
- 2014, Experimental & molecular medicine, 46, e91, 10.1038/emm.2014.6 · DOI · Paper page
- 2011, PNAS, 108, 6632, 10.1073/pnas.1017820108 · DOI · Paper page
Cited by
Items 101–175 of 175
Idova, G. V., Лазаревна, А. Е., Gevorgyan, M. M., Tikhonova, M. A., & Zhanaeva, S. Y. (2021) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-021-05075-w · Cited by 15
Seong, K.-J., Kim, H.-J., Cai, B., Kook, M.-S., Jung, J., & Kim, W.-J. (2018) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2018.22.2.145 · Cited by 15
“A recent study has shown that TLR2 is expressed abundantly in neurogenic niches of adult brain such as the hippocampus [20] of mammalian.”
BackgroundThe interplay between monocytes, α-synuclein and LRRK2 in Parkinson's disease
Strader, S., & West, A. B. (2023) · Biochemical Society Transactions · doi:10.1042/bst20201091 · Cited by 14
Simchovitz, A., Soreq, L., & Soreq, H. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.10.007 · Cited by 14
Unraveling the intricate link between cell death and neuroinflammation using Drosophila as a model
Rai, P., & Bergmann, A. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1479864 · Cited by 11
Zheng, H., Qian, X., Tian, W., & Cao, L. H. (2022) · Brain Sciences · doi:10.3390/brainsci12060774 · Cited by 12
Extracellular mixed histones are neurotoxic and modulate select neuroimmune responses of glial cells
Silva, D. E. D., Richards, C. M., McRae, S. A., Riar, I., Yang, S., Zurfluh, N. E., Gibon, J., & Klegeris, A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298748 · Cited by 10
DPP-4 inhibitor alleviates gut-brain axis pathology in Parkinson’s disease
Jeong, S. H., Kim, Y. J., Shin, J. Y., Oh, K. W., Lee, J. W., & Lee, P. H. (2025) · Gut · doi:10.1136/gutjnl-2025-334988 · Cited by 10
“21 22 On examining the tissue-specific expression of DPP-4, both protein and messenger RNA levels were found to be most abundantly expressed in the GI tract.”
Autophagy and Cell Death in Alzheimer’s, Parkinson’s and Prion Diseases
Ribarič, S., & Milisav, I. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.86706 · Cited by 10
“[232] Drouin-Ouellet J, St-Amour I, SaintPierre M, Lamontagne-Proulx J, Kriz J, Barker RA, et al.”
Feng, G., Liu, J., Wang, Y., Wang, Z., Hu, Y., Xia, Q., Xu, Y. X. Z., Shang, F., Chen, M., Wang, F., et al. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0420-x · Cited by 9
“Moreover, an approximate threefold elevation of SNCA resulted in memory deficits similar to AD mouse models in the mice of overexpressing human wild-type SNCA (Drouin-Ouellet et al. 2015).”
ResultRademacher, D. J., Exline, J. E., & Foecking, E. M. (2025) · Biomedicines · doi:10.3390/biomedicines13061400 · Cited by 10
“Toll-like receptor (TLR) overexpression can cause innate inflammatory processes to become overactive and contribute to the loss of neurons in PD. Circulating monocytes and the SNpc of PD patients have been found to have elevated levels of toll-like receptor 4 (TLR4) [169,170].”
Role of toll-like receptors in post-COVID-19 associated neurodegenerative disorders?
Satyanarayanan, S. K., Yip, T. F., Han, Z., Zhu, H., Qin, D., & Lee, S. M.-Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1458281 · Cited by 8
Parkinson’s disease: genetics and neuroinflammatory insights
Chandel, I., Kumari, S., Bagri, K., Bhatia, A., & Deshmukh, R. R. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01832-9 · Cited by 8
Jin, Y. H., Wang, L., Lin, R., He, J., Liu, D., Liu, Y., & Deng, Y. (2026) · Pharmaceuticals · doi:10.3390/ph19010157 · Cited by 7
“…receptor 4on immune cells such as macrophages and activating core inflammatory signaling pathways like NF-κ B. Research has confirmed that PD patients exhibit upregulation of TLR4 expression in peripheral blood mononuclear cells, accompanied by sustained activation of the NF-κ B pathway [78].”
The role of immune cells in the course of Parkinson's disease
He, X., Wang, R., & Wang, T. (2021) · Ibrain · doi:10.1002/j.2769-2795.2021.tb00077.x · Cited by 7
Li, X., Hao, X., Chen, C., Zhai, C., Pan, T., Zhou, X., Liu, Y., Wu, D., & Chen, X. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1421270 · Cited by 7
Kaya, Z. B., Karakoç, E., McLean, P. J., Saka, E., & Atilla, P. (2023) · FASEB BioAdvances · doi:10.1096/fba.2022-00145 · Cited by 7
Cao, X.-Y., Liu, Y., Kan, J.-S., Huang, X.-X., Kambey, P. A., Zhang, C.-T., & Gao, J. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.110970 · Cited by 6
Pan, H.-L., Ge, J.-Y., Zhang, Z.-A., Xu, J., Wu, J., Ju, Y., Zhang, X.-Y., Jiang, Z.-J., Chen, Y., Xu, Y., et al. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109016 · Cited by 5
Insulin and TLR4 Inhibitor Improve Motor Impairments in a Rat Model of Parkinson’s Disease
Hemmati, F., Valian, N., Ahmadiani, A., Mohamed, Z., Raymond, A. A., Ibrahim, N. M., & Shirazi, S. F. H. (2024) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-144200 · Cited by 6
“Experimental evidence indicates that the inflammatory response induced by α -synuclein is mediated by TLR4 (18), and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD pathology is less severe in TLR4 knockout mice than in wild-type mice (15).”
SARS-CoV-2 Spike Protein in the Pathogenesis of Prion-like DiseasesPreprint
Seneff, S., Kyriakopoulos, A. M., Nigh, G., & McCullough, P. A. (2022) · doi:10.22541/au.166069342.27133443/v1 · Cited by 5
Iba, M., Lee, Y.-J., Kwon, S., Horan-Portelance, L., Chang, K., Kim, M., Landeck, N., Rissman, R., Lee, S.-J., You, S., et al. (2025) · Experimental and Molecular Medicine · doi:10.1038/s12276-025-01564-4 · Cited by 3
TLR4 in Neurodegenerative Diseases: Alzheimer’s and Parkinson’s Diseases
Balducci, C., & Forloni, G. (2020) · Progress in inflammation research · doi:10.1007/978-3-030-56319-6_7 · Cited by 4
Bu, F., Guan, R., Wang, W., Liu, Z., Yin, S., Zhao, Y., & Chai, J. (2022) · Medicine · doi:10.1097/md.0000000000032100 · Cited by 4
“[70] In addition, TLR2 expression in specific brain regions was simultaneously positively correlated with disease stage.”
BackgroundProgress of Immunotherapies in Parkinson's Disease
Peng, Y., Kang, X., Yao, S., Zhang, X., Sugimoto, K., Liu, J., Du, M., Lin, L.-Y., Jiang, D., Chen, Q., et al. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70964 · Cited by 3
Profiling peripheral immune cells in Parkinson's disease: A scoping review
Recinto, S. J., Jernigan, J. E., Lefter, N., Vitic, Z., Overgaard, M. O., Liu, L., Howden, A. J. M., Eyer, K., Romero‐Ramos, M., Tansey, M. G., et al. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261479505 · Cited by 3
Kaur, G., Behl, T., Sehgal, A., Singh, S., Sharma, N., Kumar, A., Arora, S., & BUNGAU, S. G. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01811-z · Cited by 3
RetractedDisease mechanisms as subtypes: Immune dysfunction in Parkinson's disease
Contaldi, E., Magistrelli, L., & Comi, C. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00008-4 · Cited by 3
Chen, Y., Zhuo, Y., Wan, S., Li, Y., Chen, S., Wang, G., & Wu, N. (2025) · Journal of Functional Foods · doi:10.1016/j.jff.2025.106753 · Cited by 2
Muthmainah, M., Wiyono, N., Syah, F. K., Purnianto, A., Yudhani, R. D., & Wasita, B. (2025) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2025.05.004 · Cited by 2
“45 A large body of preclinical studies demonstrates the potential utility of NAC in the treatment of Parkinson’s disease, among other conditions.”
Regulated cell death and inflammaging in neurodegenerative disorders
Liu, H., Wen, S., Gao, X., Wu, C., Lai, B., Zhu, J., & Kong, E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-32852-7.00009-7 · Cited by 2
Targeting TLR4 in Parkinson's disease: mechanisms and therapeutic prospects
Dong, S., Lu, J., Wu, L., Wang, S., 宫玉波, Hu, J., Liu, Y., & Chen, X. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116780 · Cited by 2
Нейроиммунные механизмы нейродегенеративных заболеваний: роль цитокинов и толл-подобных рецепторов
(2018) · Сибирский вестник психиатрии и наркологии · doi:10.26617/1810-3111-2018-2(99)-99-104 · Cited by 2
Koyanagi, Y., Kassai, M., & Yoneyama, H. (2024) · Microorganisms · doi:10.3390/microorganisms12010106 · Cited by 2
Idova, G. V., Лазаревна, А. Е., Zhanaeva, S. Y., Tikhonova, M. A., & Gevorgyan, M. M. (2022) · Nauchno-prakticheskii zhurnal «Patogenez» · doi:10.25557/2310-0435.2022.03.38-43 · Cited by 2
Jin, T., Shi, R.-Z., Shi, J.-W., Liu, F., & Liang, Y. (2025) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2025.2544148 · Cited by 1
Parkinson's disease: A chronic systemic inflammatory disorder
Khan, H., & Benskey, M. J. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-21992-4.00006-3 · Cited by 1
Singh, S., Capacio, A., Braun, C. A., Carroll‐Portillo, A., Ryman, S. G., & Lin, H. C. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1672793 · Cited by 1
Tian, H., Zhao, T., Huang, X., Li, H., Ye, L., Li, Z., Li, R., Liao, R., Xu, H., Zou, L., et al. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06124-1 · Cited by 1
“TLR4 is a key pattern recognition receptor involved in innate immunity and inflammatory responses, often acti - vated by lipids or damage-associated molecular patterns [ 46 , 47].”
Piergiorge, R. M., da Silva, A. T., Francisco, R. D. S., de Vasconcelos, A. T. R., & Santos-Rebouças, C. B. (2026) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2026.111920 · Cited by 1
Taking a Toll in Brain: Role of TLR4
Krishnan, J. (2015) · Cited by 1
Changes in the Immune System in Parkinson’s Disease
Romero‐Ramos, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-64597-1_150-1 · Cited by 1
Mikroglial Toll-benzeri Reseptörlerin Alzheimer ve Parkinson Hastalıklarındaki Rolü
Samur, D. N., & Özbey, G. (2021) · Akdeniz Medical Journal · doi:10.53394/akd.981907 · Cited by 1
Immune response during idiopathic Parkinson's disease: From humans to animal models
Nissen, S. K., Ferreira, S. A., Klæstrup, I. H., & Romero‐Ramos, M. (2021) · International review of movement disorders · doi:10.1016/bs.irmvd.2021.08.006 · Cited by 1
In silico selection of damage-associated molecular patterns (DAMPS) and their receptors in humans
Oliveira, É. A., Brabosa, R. L. D. A., Bittencourt, W. J. M., Pôrto, L. C. J., Pereira, L. J., Dorneles, E. M. S., & Peconick, A. P. (2022) · Research Society and Development · doi:10.33448/rsd-v11i10.32838 · Cited by 1
Hemmati, F., Valian, N., Ahmadiani, A., Mohamed, Z., Raymond, A. A., Ibrahim, N. M., & Shirazi, S. F. H. (2024) · Physiology and Pharmacology · doi:10.61186/phypha.28.2.128 · Cited by 1
O′Neill, E. (2019) · Arrow@dit (Dublin Institute of Technology) · Cited by 1
Bureau, S. C. (2022) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2022-14889 · Cited by 1
Modulation of receptors for advanced glycation endproducts network in Parkinson's disease
Viana, S. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Concannon, R. M. (2016) · Arrow@dit (Dublin Institute of Technology) · doi:10.13025/16785
Olsen, L. K. (2018) · Arrow@dit (Dublin Institute of Technology) · doi:10.13025/17610
Exploring Mechanisms of Alpha-Synuclein Spread in Parkinson's and Atypical Parkinson's Diseases
Valdinocci, D. (2020) · Griffith Research Online · doi:10.25904/1912/1951
Sánchez-Petidier, M. (2022) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/180753
Changes in the Immune System in Parkinson’s Disease
Romero‐Ramos, M. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_150
A role for LRRK2 and Neuroinflammatory Processes in Multi-Hit Toxicant Models of Parkinson’s Disease
Rudyk, C. (2018) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2018-14444
Macias, G. V. P. (2022) · theses.fr (ABES) · doi:10.70675/2e58decbz3797z41acza4d2zc982a5ac5170
Pre-motor Mesenchymal stromal Cell Dysfunction Drives Immune Dysregulation in Parkinson’s DiseasePreprint
Ghanty, R., Mondal, K., Kamble, N. L., Yadav, R., Holla, V. V., Pal, P. K., & Datta, I. (2025) · Research Square · doi:10.21203/rs.3.rs-7957744/v1
dos Santos, T. B., Kodel, H. D. A. C., Gomes, G. D. S., Machado, T. D. O. X., Matos, D. F., Borges, R. J., Droppa‐Almeida, D., & Gomes, M. Z. (2025) · Peptide Science · doi:10.1002/pep2.70016
“TLR2 and TLR-4, upon binding to α-syn aggregates, initiate their uptake and pro-inflammatory signaling [94, 182, 183, 184].”
The role of Toll-like receptors in Parkinson's disease
Kennedy, C. (2023) · Apollo (University of Cambridge) · doi:10.17863/cam.106123
Additional file 2 of Neuroinflammation and protein pathology in Parkinson’s disease dementia
Kouli, A., Camacho, M., Allinson, K. S. J., & Williams‐Gray, C. H. (2020) · Figshare · doi:10.6084/m9.figshare.13331727
Additional file 1 of Neuroinflammation and protein pathology in Parkinson’s disease dementia
Kouli, A., Camacho, M., Allinson, K. S. J., & Williams‐Gray, C. H. (2020) · Figshare · doi:10.6084/m9.figshare.13331724
Additional file 3 of Neuroinflammation and protein pathology in Parkinson’s disease dementia
Kouli, A., Camacho, M., Allinson, K. S. J., & Williams‐Gray, C. H. (2020) · Figshare · doi:10.6084/m9.figshare.13331730
Additional file 4 of Neuroinflammation and protein pathology in Parkinson’s disease dementia
Kouli, A., Camacho, M., Allinson, K. S. J., & Williams‐Gray, C. H. (2020) · Figshare · doi:10.6084/m9.figshare.13331733
Avaliação de receptores similares a toll (tlrs) em monócitos de pacientes com doença de Parkinson
Sobrinho, H. M. D. R. (2017) · Americanae (AECID Library)
Ghanty, R., Mondal, K., Kamble, N. L., Yadav, R., Holla, V. V., Pal, P. K., & Datta, I. (2026) · Research Square · doi:10.21203/rs.3.rs-8572991/v1
Chatterjee, S., McCarty, B., Vandenberg, C. J., Bever, M., Liang, Q., Maitra, U., & Ciesla, L. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.24.714080
“…hallmark of PD. Sustained activation of innate immune glial cells, together with elevated levels of inflammatory mediators in brain tissue, perpetuates a self-reinforcing inflammatory environment that promotes neuronal dysfunction and degeneration, ultimately leading to PD-like phenotypes [45].”
Étude moléculaire de l'inflammation chronique dans la maladie de Parkinson
Compagnion, A. (2019) · theses.fr (ABES) · doi:10.70675/04ca138dz3131z4e24z884czbba2f7954a99
Yildirim-Balatan, C. (2021) · theses.fr (ABES) · doi:10.70675/3372ff2ez69a6z4970z881bze4dfe0a15571
岩田, 真. (2024) · Institutional Repositories DataBase (IRDB)
Yu, C.-Z., Ma, S.-Y., Cao, Y.-C., Xu, D., Hou, X., Liu, C.-F., Qin, Z., Luo, W., Wu, J., Liu, J., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117322
小柳, 友. (2024) · Institutional Repositories DataBase (IRDB)
Le, C., Dong, X., Bian, Y., Liu, Y., Gu, X., Zhang, X., Yang, J., & Li, L. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118531
Eikens, F., Wischhof, L., Henrich, A., Erlebach, L., Halle, A., & Scheiblich, H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.11.02.763615
Chung, L. Y.-R., Lin, Y.-T., Liu, C., Tai, Y.-C., Lin, H.-Y., Lin, C.-H., & Chen, C.-C. (2022) · doi:10.3389/fphar.2022.845930.s001
Metadata
- Authors
- Drouin-Ouellet, J., St-Amour, I., Saint-Pierre, M., Lamontagne-Proulx, J., Kriz, J., Barker, R. A., & Cicchetti, F.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Cicchetti, F.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-12-07
- Volume
- 18
- Issue
- 6
- Pages
- pyu103-pyu103
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4438545
- OpenAlex
- W2114037757
- Cited by
- 153
- References
- 63
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 19 · 2023: 11 · 2022: 21 · 2021: 19 · 2020: 17 · 2019: 12 · 2018: 19 · 2017: 7 · 2016: 6 · 2015: 5
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Parkinson Society Canada
- National Institute for Health and Care Research
- Parkinson's UK
- University of Cambridge
- Imperial College London
- Canadian Institutes of Health Research
- Fonds de Recherche du Québec - Santé
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, TLR2, TLR4, alpha-synuclein, neuroinflammation, microglia, innate immunity, circulating monocytes, B cells, caudate-putamen, synucleinopathies, dexamethasone, motor recovery, bioluminescence imaging
- MeSH terms
- Aged, Aged, 80 and over, Animals, Antiparkinson Agents, B-Lymphocytes, Brain, Dexamethasone, Disease Models, Animal, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Monocytes, Parkinson Disease, Time Factors, Up-Regulation, Case-Control Studies, Microglia, Green Fluorescent Proteins, Toll-Like Receptors, Toll-Like Receptor 2, Toll-Like Receptor 4, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.